NCT04927416View on ClinicalTrials.gov

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 25, 2021

Primary Completion Date

November 30, 2030

Study Completion Date

November 30, 2030

Conditions
Metastic Thyroid Cancer
Interventions
DRUG

68-Gallium-DOTATATE-PET/CT

68Ga-DOTATATE is administered one-time via intravenous injection of 5 mCi in a volume of 3-5 ml containing up to 50 mcg \[68Ga\] DOTATATE.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH